skip to content

Yusuf Hamied Department of Chemistry

 

Courtesy New Therapeutics Forum

Three Department of Chemistry scientists will be discussing their latest research at the Cambridge New Therapeutics Forum on Thursday 1 February in the department's BMS Lecture Theatre.

Professor Melinda Duer will open the evening by talking about her research into how enzymes produced by new bone formation can contribute to hardening or 'calcification' of the arteries and veins, which can lead to heart disease. This discovery is leading to the development of potential new treatments for these chronic diseases. 

She will be followed by Dr Robert Phipps, whose research into creating new molecules by harnessing non-covalent interactions to control selectivity, has potential applications in the development of drugs ranging from antibiotics, anti-inflammatories and asthma treatments to the latest anti-cancer drugs. 

Professor Chris Dobson will wind up the proceedings by talking about his ground-breaking work towards therapeutic approaches for Alzheimer's. Professor Dobson is co-director of the Centre for Misfolding Diseases, which will soon be housed in our new Chemistry of Health building.

The Cambridge New Therapeutics Forum is sponsored by the Cambridge Alliance on Medicines Safety.  The forum is open to all scientists interested in research and development of new therapeutics in Cambridge and the local area, including scientists at the University, Addenbrooke’s Hospital, pharmaceutical companies, biotechs, CROs, and not-for-profit organisations. The aim is to promote interactions between scientists at these organisations to improve opportunities for biotechnology research and development.

The event will open at 5pm with drinks and nibbles, and finish at 8pm. Attendance is free, but registration is required.